Content about Medicis Pharmaceutical

November 16, 2012

The Federal Trade Commission has approved a deal by Valeant Pharmaceuticals International to buy a Scottsdale, Ariz.-based drug maker.

MONTREAL — The Federal Trade Commission has approved a deal by Valeant Pharmaceuticals International to buy a Scottsdale, Ariz.-based drug maker.

Valeant said the FRC had finished reviewing its planned acquisition of Medicis Pharmaceutical and allowed the waiting period required under merger and acquisition laws to terminate early.

Valeant said the deal is still subject to conditions like the approval of Medicis' stockholders, who will have a special meeting on Dec. 7. Medicis makes drugs for asthma, fungal infections and skin conditions like acne and eczema.

September 4, 2012

Canadian drug maker Valeant Pharmaceuticals International is buying Medicis Pharmaceutical for $2.6 billion, Valeant said Monday.

MONTREAL — Canadian drug maker Valeant Pharmaceuticals International is buying Medicis Pharmaceutical for $2.6 billion, Valeant said Monday.

The $44-per-share deal, which the companies said represents a 39% premium over the closing price of Medicis' shares on Friday, is expected to close in the first half of 2013.

March 27, 2012

Hyperion Therapeutics has purchased rights to a drug for treating genetic metabolic disorders, the company said.

SOUTH SAN FRANCISCO, Calif. — Hyperion Therapeutics has purchased rights to a drug for treating genetic metabolic disorders, the company said.

Hyperion announced the purchase of Ravicti (glycerol phenylbutyrate) from Ucyclyd Pharma, a subsidiary of Medicis Pharmaceutical.